Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH chemotherapy

The purpose of our study was to identify risk factors for development of posterior reversible encephalopathy syndrome (PRES) following administration of DA-EPOCH. Out of 44 patients receiving DA-EPOCH at our institution, 3 (7%) were diagnosed with PRES. Patients who developed PRES were more likely to have a preexisting CNS insult, fluid status or electrolytes abnormalities, and hypertension.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Abby E. Floeter, Amila Patel, Melinda Tran, Marc C. Chamberlain, Paul C. Hendrie, Ajay K. Gopal, Ryan D. Cassaday Tags: Original Study Source Type: research